Overview of Dermatin Cort

Property	Description
Active Ingredients	Clotrimazole, Hydrocortisone
Form	Cream (Topical Cream)
Pharmacological Class	Antifungal Agent (Azole) and Topical Corticosteroid (Glucocorticoid)
Common Use	Simultaneous management of fungal infection and associated inflammation
Origin	Synthetic

What Type of Medicine is Dermatin Cort?

Dermatin Cort is defined as a fixed-dose combination product designed for topical use, integrating two distinct pharmacological classes into a single preparation. This medicine is a synthetic drug delivered in the form of a topical cream. Its duality places it simultaneously within the high-level classes of Antifungal Agents and Topical Corticosteroids (Glucocorticoids). This classification confirms the therapeutic focus on infections that present with an inflammatory component. The formulation is intended for application directly to the skin (Dermal Route), making it a suitable option for localized, inflamed fungal skin conditions.

Composition: The Dual Role of Clotrimazole and Hydrocortisone

The composition of Dermatin Cort is grounded in the strategic pairing of its two active ingredients: Clotrimazole and Hydrocortisone. Clotrimazole acts as the primary therapeutic agent for Targeted Fungal Control, belonging to the azole antifungal class. Conversely, Hydrocortisone is included for the Reduction of Inflammation, capitalizing on its properties as a mild glucocorticoid to modulate the body's localized immune response. This combination is widely clinically recognized for its efficacy in dual-symptom management, supporting the simultaneous need to clear the pathogen and suppress local discomfort.

The General Purpose of a Topical Antifungal and Steroid Combination

The general purpose of this topical combination is to achieve both clearance of the infection and rapid symptomatic relief through a dual therapeutic action. The formulation is intended to concurrently mitigate the fungal proliferation and suppress the associated inflammatory symptoms. The primary benefit is the quick relief from discomfort, specifically the persistent itching, pronounced redness, and minor localized swelling, which is achieved while the Clotrimazole component targets the underlying infection. This combined approach is frequently used to manage conditions like dermatomycoses where the inflammation itself contributes significantly to the patient's immediate distress.

Regulatory References

Clotrimazole Topical: MedlinePlus Drug Information

What side effects are possible with Dermatin Cort?

Possible Side Effects and Safety Information

Adverse reactions to this topical combination cream are classified in regulatory documents primarily into localized skin effects and the potential for systemic effects due to the corticosteroid component.

Classification	Common Adverse Reactions (may affect up to 1 in 10 people)
Dermatological	Burning sensation, skin irritation, pruritus (itching), redness (erythema) at the application site.

Less Common and Systemic Concerns

Serious adverse reactions are officially documented, though generally linked to improper or excessive use. The most significant systemic concern is Suppression of the Hypothalamic-Pituitary-Adrenal (HPA) Axis, which may occur due to absorption of the Hydrocortisone, particularly with prolonged use, application on large skin areas, or under occlusive dressings. Local effects such as skin atrophy (thinning) and striae (stretch marks) are also associated with extended treatment duration.

Population-Specific Considerations

Regulatory labels note that pediatric patients are more susceptible to systemic toxicity, including HPA axis suppression, due to their higher ratio of skin surface area to body weight. Contact with the eyes must be avoided to mitigate the risk of ocular effects.

This official safety profile structures the risk by distinguishing between expected, common localized reactions and the lower probability of serious systemic consequences that are explicitly tied to duration and application constraints in government prescribing information.

Overdose and Emergency Response

The documented profile for Dermatin Cort overdose centers on the potential for systemic toxicity arising from the hydrocortisone component. This risk increases with prolonged or excessive use, application over large body surface areas, or use under occlusive dressings, as these circumstances facilitate systemic absorption.

Over-absorption may lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is the core physiological abnormality documented in regulatory materials. Manifestations of systemic overdose include the development of clinical features associated with excess corticosteroid exposure, commonly known as Hypercorticalism (Cushing’s Syndrome). Specific adverse ophthalmic effects, such as Glaucoma or Cataract, are also documented with long-term overuse.

A severe, life-threatening outcome associated with HPA axis suppression is Acute Glucocorticosteroid Insufficiency, which may particularly present if the medicine is abruptly stopped after prolonged application. Due to this severity, regulatory authorities mandate that individuals seek immediate medical attention if symptoms indicative of Adrenal Suppression—such as severe fatigue, low blood pressure, or fainting—are observed.

In overdose situations, symptomatic and supportive treatment is the officially described intervention. Pediatric patients are noted in official labeling to demonstrate greater susceptibility to systemic toxicity due to their body surface area ratio. Monitoring of the HPA axis status is required for patients considered at high risk of systemic absorption.

Therapeutic Uses of Dermatin Cort

What Dermatin Cort Treats: Main Uses and Benefits

This medication is commonly used across conditions characterized by fungal infections where the presentation is complicated by heightened inflammation. This cream is relevant for symptomatic management in conditions such as certain cases of Tinea (ringworm, athlete's foot, jock itch) and Cutaneous Candidiasis. It helps address symptom clusters that require dual therapeutic management, and is used in areas where short-term symptom management is appropriate. This approach is applied across domains where additional symptomatic support is needed.

The medicine is often applied in scenarios where patients experience noticeable physical discomfort from symptoms like intense itching (pruritus), a noticeable burning sensation, and visible redness. It contributes to symptomatic relief, which may assist patients in maintaining day-to-day comfort during symptomatic periods, and is applied when symptoms may interfere with routine activities. This supportive approach contributes to easing the overall symptom load.

Quick Fact: May assist with managing intense itching and redness

Eligibility and Restrictions for Use

Dermatin Cort is an anti-fungal and corticosteroid combination medicine with specific population-eligibility rules defined by official regulatory bodies to manage the risks associated with the steroid component.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Adolescents (age 10 and over) for short-term application [Source: Regulatory SmPC]. Older Adults may use the medicine without a specific dosage adjustment.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to the active ingredients (Clotrimazole, Hydrocortisone). Patients with Viral skin diseases (e.g., herpes, chicken pox), Untreated bacterial skin diseases, or conditions like acne, rosacea, or perioral dermatitis [Source: Regulatory SmPC].
Age-related eligibility rules	Use is contraindicated in children under 10 years of age, unless specifically prescribed by a physician [Source: Regulatory Portal]. Infants and small children are more susceptible to systemic toxicity (HPA axis suppression).
Pregnancy and lactation eligibility status	Use during both pregnancy and lactation is contraindicated/not recommended, unless prescribed by a physician after a careful risk assessment [Source: Regulatory SmPC].

Eligibility-Related Restrictions

Regulatory documents impose several restrictions on use:

Duration: Treatment is restricted to a maximum of seven days.
Site: Prohibited from use on the face, eyes, mouth, or mucous membranes, and on broken skin.
Application Method: Restricted from use under occlusive dressings (including nappies) and on large body surface areas (more than 5–10%), as this increases systemic absorption risk [Source: Regulatory SmPC].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dermatin Cort (Clotrimazole/Hydrocortisone topical cream) primarily by addressing additive exposure risks and physical product interactions, rather than systemic drug-drug interactions. Because of the minimal systemic absorption of the active ingredients following topical use, official prescribing information notes that no interaction studies have been performed to assess many systemic drug combinations.

Official Interaction Statements

Classification	Constraint or Outcome
Exposure Risk with Other Corticosteroids	Co-administration with other corticosteroid-containing products may result in an additive increase in total systemic glucocorticoid exposure.
Physical Product Interaction	The cream may cause damage to latex contraceptive products (e.g., condoms, diaphragms), leading to a reduction in their effectiveness.
Timing-Based Restriction	Alternative contraceptive precautions for at least five days are required following application to the vulva or penis due to the latex product interaction.
Population-Specific Note	Use in infants and children under occlusive dressings (including tight-fitting diapers) formally increases the systemic absorption of the Hydrocortisone component.

This profile details specific constraints regarding concomitant use with other steroids and establishes mandatory timing rules for co-use with latex products, based on physical and exposure-related risks documented in regulatory labeling.

Mechanism of Action

Dermatin Cort (hydrocortisone) is a synthetic glucocorticoid receptor (GR) agonist. Following percutaneous absorption and entry into target cells, the compound binds to the cytosolic GR, forming a ligand-receptor complex. This complex then translocates into the cell nucleus.

Inside the nucleus, the complex engages specific DNA sequences, known as Glucocorticoid Response Elements (GREs), located within the promoter regions of target genes. This binding event modulates gene transcription. Specifically, the complex upregulates the transcription of anti-inflammatory mediators, such as Lipocortin-1 (Annexin A1). Lipocortin-1 inhibits phospholipase A2, which consequently reduces the liberation of arachidonic acid from membrane phospholipids.

This inhibition results in a decreased biosynthesis of pro-inflammatory eicosanoids, including prostaglandins and leukotrienes. Concurrently, the GR complex directly suppresses the gene expression of numerous pro-inflammatory cytokines (e.g., interleukins, TNF-alpha) and inducible enzymes (e.g., COX-2, iNOS), ultimately reducing the local concentration of cellular and molecular mediators of inflammation and modulating the systemic immune response.

Dosage and Administration Information

How to Use Dermatin Cort

Dermatin Cort (Clotrimazole/Hydrocortisone cream) is designed for topical administration only, applied directly to the affected skin surface. Standard usage patterns dictate precise constraints regarding frequency, duration, and application boundaries to ensure correct utilization of this dual-component preparation.

Official Administration Guidelines

Feature	Guideline
Route of Administration	Topical (Dermal application)
Dosing Schedule	Apply a thin, even layer to the affected area. The dosage is typically limited by a high-level maximum daily allowance (e.g., 10 mg of cream per kg body weight).
Frequency	Must be applied twice daily (B.I.D.).
Treatment Duration	The course is strictly limited to a maximum of seven days.
Age Restriction	Approved for use in adults and children aged 10 years and over.

Procedural Usage Rules

The usage protocol is based on short-term application to confined areas. The cream must be gently rubbed in until absorbed. Application is restricted to small skin areas only, and contact with the face, eyes, or mucous membranes is forbidden. Following the 7-day regimen for the combination cream, it is indicated that treatment may be transitioned to an antifungal-only product for a subsequent period to address the fungal component exclusively.

Recent Clinical Evidence

Dermatin Cort: Research evidence / Overview of studies

Evidence for use in Inflamed Superficial Fungal Infections

Research on the combination cream has been studied for conditions where a fungal infection occurs alongside noticeable inflammation, such as athlete's foot, ringworm, and cutaneous candidiasis. Studies exploring the use in these conditions have primarily included short-term, randomized controlled trials (RCTs). These trials primarily examined outcomes related to both fungal presence and outcomes related to physical discomfort, such as itching and redness. Findings describe patterns observed in the studies, including an observed initial change in the measurement of subjective symptoms when the combination was compared to the antifungal ingredient used alone or a vehicle cream. The combination was studied in trials comparing outcomes related to clinical sign monitoring and monitoring the presence of fungus. The evidence contributes to the broader evidence landscape, but evidence quality varies across studies when comparing it against other antifungal strategies.

Long-term studies and follow-up

The majority of formal research was studied for this cream over a defined short-term interval, typically spanning one to two weeks of continuous use. Studies report that follow-up durations were limited when examining the long-term history of the skin condition, meaning long-term effects are not fully established in the existing evidence. Evidence for maintenance or recurrence patterns was generally tracked only for a short time following the conclusion of the initial treatment period. The research exploring long-term symptom patterns or consistency of observed changes beyond this period was observed to be limited.

Evidence in special populations

Research exploring the combination was evaluated in various populations. While the studies primarily involved adults, specific research explored its use in children and infants, particularly for conditions associated with acute or disruptive episodes like candidal napkin dermatitis. Findings describe group patterns, and results apply only to the populations studied. Data for certain groups remain insufficient; for instance, evidence for older adults or patients with certain pre-existing chronic conditions is limited in specialized trials.

What is still uncertain about Dermatin Cort research

The research landscape highlights areas where more study is still ongoing. One area of uncertainty is that comparative evidence is limited regarding research against other antifungal monotherapies. Studies have explored outcomes describing episodic or acute changes in symptoms, such as itching. However, researchers noted that precisely measuring these individual symptoms can be challenging, meaning that evidence quality varies when assessing subjective discomfort. These research findings describe group patterns, not personal outcomes, and reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Dermatin Cort (FAQ)

Q: What should I do if I accidentally get Dermatin Cort in my eye?

A: According to official regulatory protocol, if the cream accidentally contacts the eyes, the area should be flushed immediately and thoroughly. The protocol involves using a large amount of water for at least 15 minutes. Official guidance states that a healthcare professional should be consulted if any irritation persists after rinsing.

Q: Does Dermatin Cort affect my immune system generally?

A: The corticosteroid (Hydrocortisone) component in Dermatin Cort is described as modulating the local inflammatory response. Official documents state that its mechanism of action includes modulating the systemic immune response. Additionally, if enough of the cream is absorbed into the bloodstream, it can temporarily suppress the hypothalamic-pituitary-adrenal (HPA) axis, which is part of the body's stress response system.

Q: What does 'topical use only' mean for Dermatin Cort?

A: The phrase "topical use only" means that the medicine is exclusively approved for application onto the skin (the dermal route). The medicine is prohibited from being swallowed or used inside the mouth, eyes, or other mucous membranes. This restriction ensures the medicine is used only as intended for localized skin conditions.

Q: Can Dermatin Cort make other skin conditions worse?

A: Official contraindications list several conditions where Dermatin Cort should not be used. This includes viral skin diseases, such as herpes or chicken pox, and untreated bacterial skin diseases. The regulatory warnings are in place because the corticosteroid component may worsen the course of these specific conditions.

Q: How long after starting Dermatin Cort should I expect to see a change?

A: Official patient information does not specify an exact timeframe for initial changes. However, regulatory documents state that a healthcare professional should be consulted if symptoms do not show improvement within a period of 1 to 2 weeks of use. This timeframe is often used as a benchmark for assessing the initial effects of the medicine.

Q: What is the difference between Dermatin Cort and other cortisone creams?

A: Dermatin Cort is defined as a fixed-dose combination product containing two active ingredients: a topical corticosteroid (Hydrocortisone) and an antifungal agent (Clotrimazole). This differs from many other cortisone creams, which contain only the single steroid component. The combination is intended to treat a fungal infection while simultaneously reducing the associated inflammation.

Q: Are there any specific foods or drinks to avoid while using Dermatin Cort?

A: Regulatory documents generally do not describe specific dietary constraints that need to be followed while using this topical cream. This is due to the minimal systemic absorption of the active ingredients when the product is used correctly on the skin.

Q: What happens if I forget to apply Dermatin Cort one time?

A: Official patient information provides guidance on a protocol for missed applications. This guidance describes using the forgotten application as soon as remembered, unless it coincides with the next scheduled time. The official guidance specifically prohibits the use of a double amount to compensate for a missed application.

Q: Is Dermatin Cort available without a prescription?

A: The availability of Dermatin Cort depends on its regulatory classification in a given country. This classification determines if the product is designated as prescription-only or if it can be supplied by a pharmacy without a prescription. This restriction is based on the components of the fixed-dose combination.

Q: Why is it described as a 'medium-potency' steroid?

A: Official documentation classifies the Hydrocortisone ingredient as a low-potency or mild topical corticosteroid. The specific potency of the steroid is a factor that determines the approved short duration of use and helps to limit the risk of systemic effects.

Q: What are the ingredients listed as 'inactive' in Dermatin Cort?

A: Regulatory documents, such as the full product information, list all the ingredients included in the cream. These are called inactive ingredients, or excipients, and they are used to form the cream base, help deliver the active medicine, or maintain the product's quality. They are not intended to have a direct therapeutic effect.

Q: Can Dermatin Cort cause skin discoloration?

A: Official safety information indicates that skin discoloration has been reported as an uncommon or infrequent side effect associated with the use of similar topical corticosteroid products. This may involve either a lightening or a darkening of the skin in the area of application.

Q: Does Dermatin Cort interact with common vitamins or supplements?

A: Regulatory documents generally note that there are no specific interaction studies available regarding the use of Dermatin Cort with common vitamins or supplements. This is due to the minimal absorption of the active ingredients into the bloodstream following proper topical application.

Q: Is Dermatin Cort known to cause withdrawal symptoms when stopped?

A: The medicine is approved for short-term use, typically a maximum of seven days, and contains a low-potency corticosteroid. This short duration and mild nature are factors that distinguish its use from the long-term use of more potent corticosteroid creams. Withdrawal-like symptoms are primarily associated with the sudden cessation of prolonged use of the more potent forms.

Q: Is Dermatin Cort available in different strengths?

A: Official regulatory documents specify the authorized concentration of the active ingredients (Clotrimazole and Hydrocortisone). This specific concentration is generally the only strength officially approved and made available for this fixed-dose combination product.

Q: Are there any restrictions on sun exposure while using Dermatin Cort?

A: Official product information contains a warning that the cream may make skin more sensitive to sunlight. As a precaution, sun protection is often referenced in the official guidance, as is the avoidance of sunlamps and tanning beds.

Q: Can Dermatin Cort affect blood sugar levels?

A: Because the medicine contains the corticosteroid Hydrocortisone, systemic absorption can theoretically affect blood sugar control. Official regulatory documents contain a caution statement for use by patients with diabetes mellitus.

Q: How long is Dermatin Cort typically good for after the tube is opened?

A: Official patient information leaflets often specify a particular shelf life for the cream after the tube has been opened for the first time. This may be expressed as a time constraint, typically 3 or 6 months, provided that the required storage conditions are maintained.

How should Dermatin Cort be stored and disposed of?

Dermatin Cort (Clotrimazole/Hydrocortisone) cream must be stored and handled according to specific government-approved regulatory requirements to ensure product integrity and safety.

Required Storage Conditions

Temperature: Store the cream at a temperature below 25 C (77 F). The product must not be refrigerated or frozen.
Container and Handling: The medicine must be kept in its original container and the container must be kept tightly closed to protect it.
Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused cream must not be thrown away via wastewater systems or general household waste. Disposal must follow local requirements for the collection and discarding of medicinal products.

Dermatin Cort